Novogen (KZIA) Competitors

$13.45 +0.61 (+4.75%)

Closing price 04:00 PM Eastern

Extended Trading

$13.06 -0.39 (-2.86%)

As of 07:43 PM Eastern

KZIA vs. XBIT, SPRB, LONA, ATYR, and IMMP

Should you be buying Novogen stock or one of its competitors? The main competitors of Novogen include XBiotech (XBIT), Spruce Biosciences (SPRB), Athira Pharma (LONA), aTyr Pharma (ATYR), and Prima BioMed (IMMP). These companies are all part of the "pharmaceutical products" industry.

How does Novogen compare to XBiotech?

Novogen (NASDAQ:KZIA) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

: In the previous week, Novogen and Novogen both had 1 articles in the media. XBiotech's average media sentiment score of 0.00 beat Novogen's score of -1.32 indicating that XBiotech is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
XBiotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Novogen has higher revenue and earnings than XBiotech.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novogen $42K 529.35 -$13.41M N/A N/A
XBiotech N/A N/A -$45.54M -$1.50 N/A
: 30.9% of Novogen shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Novogen has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
: Novogen presently has a consensus target price of $21.00, indicating a potential upside of 56.13%. Given Novogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Novogen is more favorable than XBiotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
XBiotech
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Novogen's return on equity of 0.00% beat XBiotech's return on equity.
Company Net Margins Return on Equity Return on Assets
Novogen N/A N/A N/A
XBiotech N/A -27.80% -26.67%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
XBiotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	529.35	-$13.41M	N/A	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
XBiotech	N/A	-27.80%	-26.67%

Summary

Novogen beats XBiotech on 8 of the 11 factors compared between the two stocks.

How does Novogen compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

: In the previous week, Spruce Biosciences and Spruce Biosciences both had 1 articles in the media. Spruce Biosciences' average media sentiment score of 0.23 beat Novogen's score of -1.32 indicating that Spruce Biosciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spruce Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
: Novogen has higher revenue and earnings than Spruce Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spruce Biosciences N/A N/A -$38.97M -$51.72 N/A
Novogen $42K 529.35 -$13.41M N/A N/A
: 91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Spruce Biosciences has a beta of 3.26, meaning that its stock price is 226% more volatile than the S&P 500. Comparatively, Novogen has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.
: Spruce Biosciences presently has a consensus price target of $190.60, suggesting a potential upside of 221.20%. Novogen has a consensus price target of $21.00, suggesting a potential upside of 56.13%. Given Spruce Biosciences' higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Novogen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spruce Biosciences
1 Sell rating(s)
2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.50
Novogen
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Novogen's return on equity of 0.00% beat Spruce Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Spruce Biosciences N/A -203.99% -127.96%
Novogen N/A N/A N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-$38.97M	-$51.72	N/A
Novogen	$42K	529.35	-$13.41M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-203.99%	-127.96%
Novogen	N/A	N/A	N/A

Summary

Spruce Biosciences beats Novogen on 6 of the 10 factors compared between the two stocks.

How does Novogen compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Novogen (NASDAQ:KZIA) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

: Athira Pharma presently has a consensus price target of $10.00, suggesting a potential upside of 3.84%. Novogen has a consensus price target of $21.00, suggesting a potential upside of 56.13%. Given Novogen's stronger consensus rating and higher possible upside, analysts clearly believe Novogen is more favorable than Athira Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
Novogen
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Novogen has higher revenue and earnings than Athira Pharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Athira Pharma N/A N/A -$105.61M -$9.68 N/A
Novogen $42K 529.35 -$13.41M N/A N/A
: Novogen's return on equity of 0.00% beat Athira Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Athira Pharma N/A -340.97% -209.91%
Novogen N/A N/A N/A
: Athira Pharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Novogen has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.
: 57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 25.1% of Athira Pharma shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: In the previous week, Athira Pharma and Athira Pharma both had 1 articles in the media. Novogen's average media sentiment score of -1.32 beat Athira Pharma's score of -1.74 indicating that Novogen is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Athira Pharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Very Negative
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$9.68	N/A
Novogen	$42K	529.35	-$13.41M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-340.97%	-209.91%
Novogen	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

Novogen beats Athira Pharma on 9 of the 11 factors compared between the two stocks.

How does Novogen compare to aTyr Pharma?

Novogen (NASDAQ:KZIA) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

: Novogen currently has a consensus price target of $21.00, suggesting a potential upside of 56.13%. aTyr Pharma has a consensus price target of $25.67, suggesting a potential upside of 2,947.57%. Given aTyr Pharma's higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Novogen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
aTyr Pharma
1 Sell rating(s)

5 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Novogen has higher earnings, but lower revenue than aTyr Pharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novogen $42K 529.35 -$13.41M N/A N/A
aTyr Pharma $190K 434.62 -$74.12M -$0.79 N/A
: Novogen's return on equity of 0.00% beat aTyr Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Novogen N/A N/A N/A
aTyr Pharma N/A -99.87% -74.41%
: Novogen has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
: 30.9% of Novogen shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: In the previous week, aTyr Pharma had 1 more articles in the media than Novogen. MarketBeat recorded 2 mentions for aTyr Pharma and 1 mentions for Novogen. aTyr Pharma's average media sentiment score of 0.00 beat Novogen's score of -1.32 indicating that aTyr Pharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
aTyr Pharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	529.35	-$13.41M	N/A	N/A
aTyr Pharma	$190K	434.62	-$74.12M	-$0.79	N/A

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
aTyr Pharma	N/A	-99.87%	-74.41%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Novogen beats aTyr Pharma on 7 of the 13 factors compared between the two stocks.

How does Novogen compare to Prima BioMed?

Novogen (NASDAQ:KZIA) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

: Company Net Margins Return on Equity Return on Assets
Novogen N/A N/A N/A
Prima BioMed N/A N/A N/A
: Novogen currently has a consensus price target of $21.00, suggesting a potential upside of 56.13%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,096.69%. Given Prima BioMed's higher possible upside, analysts clearly believe Prima BioMed is more favorable than Novogen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Prima BioMed
1 Sell rating(s)

3 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.75
: 30.9% of Novogen shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 3.1% of Prima BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: In the previous week, Prima BioMed had 6 more articles in the media than Novogen. MarketBeat recorded 7 mentions for Prima BioMed and 1 mentions for Novogen. Prima BioMed's average media sentiment score of 0.07 beat Novogen's score of -1.32 indicating that Prima BioMed is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
Prima BioMed
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
: Novogen has higher earnings, but lower revenue than Prima BioMed.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novogen $42K 529.35 -$13.41M N/A N/A
Prima BioMed $4.08M 16.60 -$39.78M N/A N/A
: Novogen has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Prima BioMed	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	529.35	-$13.41M	N/A	N/A
Prima BioMed	$4.08M	16.60	-$39.78M	N/A	N/A

Summary

Prima BioMed beats Novogen on 6 of the 11 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.23M	$3.39B	$6.24B	$11.86B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	N/A	38.85	29.04	28.48
Price / Sales	529.35	157.28	477.10	60.43
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	-2.52	7.03	9.67	6.67
Net Income	-$13.41M	$23.62M	$3.55B	$332.64M
7 Day Performance	13.50%	3.67%	1.70%	2.01%
1 Month Performance	83.24%	7.17%	5.62%	9.19%
1 Year Performance	277.81%	67.04%	34.42%	39.59%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	1.5151 of 5 stars	$13.45 +4.8%	$21.00 +56.1%	N/A	$22.23M	$42K	N/A	12	Negative News
XBIT XBiotech	0.2601 of 5 stars	$2.54 -1.6%	N/A	N/A	$78.51M	N/A	N/A	100	News Coverage Positive News Upcoming Earnings
SPRB Spruce Biosciences	2.3014 of 5 stars	$54.77 -4.2%	$190.60 +248.0%	N/A	$78.47M	N/A	N/A	20
LONA Athira Pharma	0.7624 of 5 stars	$8.69 +4.1%	$10.00 +15.1%	N/A	$78.44M	N/A	N/A	40	Gap Up
ATYR aTyr Pharma	1.2461 of 5 stars	$0.79 +0.3%	$25.67 +3,134.2%	N/A	$77.55M	$190K	N/A	53	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. XBIT, SPRB, LONA, ATYR, and IMMP

How does Novogen compare to XBiotech?

Summary

How does Novogen compare to Spruce Biosciences?

Summary

How does Novogen compare to Athira Pharma?

Summary

How does Novogen compare to aTyr Pharma?

Summary

How does Novogen compare to Prima BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. XBIT, SPRB, LONA, ATYR, and IMMP

How does Novogen compare to XBiotech?

Summary

How does Novogen compare to Spruce Biosciences?

Summary

How does Novogen compare to Athira Pharma?

Summary

How does Novogen compare to aTyr Pharma?

Summary

How does Novogen compare to Prima BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools